Epitope of RSV fusion protein and antibody recognizing the same

US9856313B2 · kind B2 · utility

Assignees

• XIAMEN UNIVERSITY · CN
• Xiamen Innovax Biotech Co., Ltd. · CN
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Zizheng Zheng · Xiamen, CN
• Jason McLellan · Austin, US
• Man Chen · Shanghai, CN
• Min Zhao · Shanghai, CN
• Liangmin Huang · Xiamen, CN
• Barney Graham · Rockville, US
• Ningshao Xia · Fujian, CN

Key dates

• Filing date: Mar 17, 2014
• Grant date: Jan 2, 2018
• Expiry date: Jun 25, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18534
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.